Entrar/Registro  
INICIO ENGLISH
 
Dermatología Revista Mexicana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Dermatología Revista Mexicana >Año 2019, No. 5


González-Hernández WC, Méndez-Juárez A, Sánchez-Álvarez I
Tratamientos emergentes de la alopecia areata
Dermatología Rev Mex 2019; 63 (5)

Idioma: Español
Referencias bibliográficas: 58
Paginas: 469-480
Archivo PDF: 509.09 Kb.


Texto completo




RESUMEN

La unidad folicular constituye un modelo inmunológico no completamente comprendido; a pesar de los avances moleculares, seguimos ignorando su maquinaria inmunológica. La autorreactividad contra autoantígenos y antígenos desconocidos, los puntos de control inmunológico y el estado del microbioma intestinal son piezas fundamentales de este rompecabezas. Esta enfermedad afecta la calidad de vida de los pacientes por el aspecto estético y en algunos casos por los efectos adversos de los tratamientos debido a la falta de respuesta. El arsenal terapéutico hoy en día es basto; existen múltiples fármacos con resultados inferiores comparados con los de las terapias de primera línea (corticoesteroides); sin embargo, han surgido nuevas terapias dirigidas con resultados prometedores. El propósito de esta revisión es mencionar las opciones emergentes para el tratamiento de la alopecia areata.


Palabras clave: Alopecia areata, autoinmunidad, pelo.


REFERENCIAS

  1. Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primer. 2017;3:17011.

  2. Skogberg G, Jackson S, Astrand A. Mechanisms of tolerance and potential therapeutic interventions in alopecia areata. Pharmacol Ther 2017;179:102-110.

  3. Cervantes J, Fertig RM, Maddy A, Tosti A. Alopecia areata of the beard: A review of the literature. Am J Clin Dermatol 2017 Dec;18(6):789-796.

  4. Strazzulla LC, Wang EH, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata. Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018;78(1):1-12.

  5. Restrepo R, Calonje E. McKee’s Pathology of the Skin. Elsevier. 2012; 967-1050.

  6. Goh C, Finkel M, Christos P, Sinha A. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006;20(9):1055-60.

  7. Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 2009;23(2):240-1.

  8. Gandhi V, Baruah MC, Bhattacharaya SN. Nail changes in alopecia areata: Incidence and pattern. Indian J Dermatol Venereol Leprol 2003 Mar-Apr;69(2):114-5.

  9. Molina L, Donati A, Valente NSY, Romiti R. Alopecia areata incognita. Clinics (Sao Paulo) 2011;66(3):513-5.

  10. Pratt H, King L, Messenger A, et al. Alopecia areata. Nature Rev 2017;3:1-17.

  11. Galán-Gutiérrez M, Rodríguez-Bujaldón A, Moreno-Giménez JC. Actualización terapéutica en alopecia areata. Actas Dermo-Sifiliográficas 2009;100(4):266-76.

  12. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: A long term follow-up study of 191 patients. J Am Acad Dermatol 2006;55(3):438-41.

  13. Spano F, Donovan JC. Alopecia areata: Part 1: pathogenesis, diagnosis, and prognosis. Can Fam Physician 2015 Sep;61(9):751-5.

  14. Jha AK, Udayan UK, Roy PK, Amar AKJ, Chaudhary RKP. Dermoscopy of alopecia areata-a retrospective analysis. Dermatol Pract Concept.2017;7(2):53-7.

  15. Mane M, Nath AK, Thappa DM. Utility of dermoscopy in alopecia areata. Indian J Dermatol 2011;56(4):407-11.

  16. Guttikonda AS, Aruna C, Ramamurthy D, Sridevi K, Alagappan SKL. Evaluation of clinical significance of dermoscopy in alopecia areata. Indian J Dermatol 2016;61(6):628.

  17. Pirmez R. Revisiting Coudability hairs in Alopecia areata: The story behind the name. Skin Appendage Disord 2016;2(1-2):76-8.

  18. Navarrete-Dechent C, Moll-Manzur C, Droppelmann N, González S. Actualización en el uso de la biopsia de piel por punch. Rev Chil Cir 2016;68(6):467-73.

  19. Werner B1, Mulinari-Brenner F. Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata - part II. An Bras Dermatol 2012 Nov- Dec;87(6):884-90.

  20. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003 Dec;139(12):1555-9.

  21. Bernárdez C, Molina-Ruiz AM, Requena L. Histopatología de las alopecias. Parte I: alopecias no cicatriciales. Actas Dermo-Sifiliográficas 2015;106(3):158-67.

  22. Yoon TY, Lee DY, Kim YJ, Lee JY, Kim MK. Diagnostic usefulness of a peribulbar eosinophilic infiltrate in alopecia areata. JAMA Dermatol 2014;150(9):952-6.

  23. Müller CSL, Shabrawi-Caelen LE. ‘Follicular Swiss cheese’ pattern – another histopathologic clue to alopecia areata. J Cutan Pathol 2011;38(2):185-9.

  24. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG, British Association of Dermatologists. Guidelines for the management of alopecia areata. Br J Dermatol 2003;149(4):692-9.

  25. Trüeb RM, Dias MFRG. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol 2018 Feb;54(1):68-87.

  26. Santos Z, Avci P, Hamblin M. Drug discovery for alopecia: gone today, hair tomorrow. Expert Opin Drug Discov 2015;10(3):269-92.

  27. Hordinsky, M. Current treatments for alopecia areata. J Investig Dermatol Symp 2015;17:44-6.

  28. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol 2018 Jan;78(1):15-24.

  29. Jun M, Lee N, Lee W. Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprenhensive review of 353 cases over 22 years. J Dermatol 2017;44:386-93.

  30. Zarei M, Wikramanayake TC, Falto-Aizpurua L, Schachner LA, Jimenez JJ. Low level laser therapy and hair regrowth: an evidence-based review. Lasers Med Sci 2016;31(2):363- 71.

  31. Wikramanayake TC, Villasante AC, Mauro LM, Nouri K, Schachner LA, Perez CI, et al. Low-level laser treatment accelerated hair regrowth in a rat model of chemotherapy-induced alopecia (CIA). Lasers Med Sci 2013;28(3):701-6.

  32. Mlacker S, Aldahan AS, Simmons BJ, Shah V, McNamara CA, Samarkandy S, et al. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther 2017 Apr;19(2):93-99.

  33. Escalas J. Fotodermatología . 4ª Ed. México, 2014; cap 5.

  34. Gupta A, Carviel J, Abramovits W. Treating alopecia areata: Current practices versus new directions. Am J Clin Dermatol 2017;18:67-75.

  35. Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. An overview of the biology of platelet-rich plasma and microneedling as potential treatments for alopecia areata. J Investig Dermatol Symp Proc 2018 Jan;19(1):S21-S24.

  36. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of plateletrich plasma on alopecia areata. Br J Dermatol 2013;169(3):690-694.

  37. Lee S, Lee W-S. Management of alopecia areata: Updates and algorithmic approach. J Dermatol 2017 Nov;44(11):1199-1211.

  38. Amirnia M, Mahmoudi S-S, Karkon-Shayan F, Alikhah H, Piri R, Naghavi-Behzad M, et al. Comparative study of intralesional steroid injection and cryotherapy in alopecia areata. Niger Med J 2015 Jul-Aug;56(4):249-52.

  39. Chiang KS, Mesinkovska NA, Piliang MP, Bergfeld WF. Clinical efficacy of diphenylcyclopropenone in alopecia areata: Retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc 2015 Nov;17(2):50-5.

  40. Yoshimasu T, Furukawa F. Modified immunotherapy for alopecia areata. Autoimmun Rev 2016;15(7):664-7.

  41. Hill ND, Bunata K, Hebert AA. Treatment of alopecia areata with squaric acid dibutylester. Clin Dermatol 2015;33(3):300-4.

  42. Durdu M, Özcan D, Baba M, Seçkin D. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol 2015;72(4):640-50.

  43. Barbosa CP, Bracht L, Ames FQ, de Souza Silva-Comar FM, Tronco RP, Bersani-Amado CA. Effects of ezetimibe, simvastatin, and their combination on inflammatory parameters in a rat model of adjuvant-induced arthritis. Inflammation 2017;40(2):717-24.

  44. Lattouf C, Jimenez J, Tosti A, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol 2014;72(2):359-61.

  45. Ali A, Martin JM. Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol 2010;9(1):62-4.

  46. Loi, C, Starace, M, Piraccini, B. Alopecia areata (AA) and treatment with simvastatin/ezetimibe: Experience of 20 patients. J Am Acad Dermatol 2016 May;74(5):e99-e100.

  47. Freitas M, Trüeb RM. Unsuccessful treatment of alopecia areata with simvastatin/ezetimibe: experience in 12 patients. Skin Appendage Disord 2017 Aug;3(3):156-60.

  48. Damsky W, King B. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol 2017 Apr;76(4):736-744.

  49. Shreberk-Hassidim R, Ramot Y, Zlotgorski A. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol 2017.

  50. Meephansan J, Thummakriengkrai J, Ponnikorn S, Yingmema W, Deenonpoe R, et al. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. Arch Dermatol Res 2017;309(9):729-38.

  51. Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of action, clinical applications, current and future perspectives. Curr Med Chem 2017;24(28):3054-67.

  52. Gilhar A, Schrum AG, Etzioni A, Waldmann H, Paus R. Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev 2016 Jul;15(7):726-35.

  53. Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol 2017;77(4):773-4.

  54. Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/ PD-L1 inhibitors in haematological malignancies: update 2017 Immunology 2017 Nov;152(3):357-371.

  55. John KK-G, Brockschmidt FF, Redler S, Herold C, Hanneken S, Eigelshoven S, et al. Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol 2011;131(5):1169-72.

  56. Renert Y, Guttman E. The changing landscape of alopecia areata: The therapeutic paradigm. Adv Ther 2017 Jul;34(7):1594-1609.

  57. Li Y, Yan B, Wang H, Li H, Li Q, et al. Hair regrowth in alopecia areata patients following. Stem Cell Educator therapy. BMC Med 2015;13:87.

  58. Hoang MP, Keady M, Mahalingam M. Stem cell markers (cytokeratin 15, CD34 and nestin) in primary scarring and nonscarring alopecia. Br J Dermatol 2009 Mar;160(3):609- 15.



>Revistas >Dermatología Revista Mexicana >Año2019, No. 5
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019